United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for CASI Pharmaceuticals, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | -301.8% | -729.14% | -595.38% | -661.66% | -687.91% | -683.87% |
|---|---|---|---|---|---|---|
| ROA | -60.89% | -30.99% | -29.77% | -33.08% | -34.4% | -34.19% |
| Gross Margin | 39.06% | 33.24% | 31.97% | 31.13% | 29.42% | 29.65% |
| Net Margin | -137.57% | -52.59% | -49.81% | -53.12% | -55.07% | -54.52% |
| Total Assets | $53,674.00K | $57,302.42K | $61,262.31K | $65,584.30K | $70,301.90K | $75,237.52K |
| Net Income | -$39,258.00K | -$17,193.54K | -$17,647.79K | -$20,982.40K | -$23,369.52K | -$24,882.36K |